Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) and Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations for Recursion Pharmaceuticals and Acrivon Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Recursion Pharmaceuticals | 1 | 2 | 2 | 0 | 2.20 |
| Acrivon Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Recursion Pharmaceuticals currently has a consensus target price of $9.40, indicating a potential upside of 189.23%. Acrivon Therapeutics has a consensus target price of $11.67, indicating a potential upside of 602.81%. Given Acrivon Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Recursion Pharmaceuticals.
Risk and Volatility
Profitability
This table compares Recursion Pharmaceuticals and Acrivon Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Recursion Pharmaceuticals | -863.37% | -63.98% | -47.05% |
| Acrivon Therapeutics | N/A | -54.10% | -48.67% |
Valuation & Earnings
This table compares Recursion Pharmaceuticals and Acrivon Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Recursion Pharmaceuticals | $74.68 million | 22.95 | -$644.76 million | ($1.48) | -2.20 |
| Acrivon Therapeutics | N/A | N/A | -$80.56 million | ($2.13) | -0.78 |
Acrivon Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Acrivon Therapeutics beats Recursion Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
